Identification of a strong and specific antichlamydial N-acylhydrazone

Huirong Zhang¹, Anuj Kunadia², Yingfu Lin²*, Joseph D. Fondell¹, Daniel Seidel²*, Huizhou Fan¹*

¹ Department of Pharmacology, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America, ² Department of Chemistry and Chemical Biology, School of Arts and Sciences, Rutgers, The State University of New Jersey, Piscataway, New Jersey, United States of America

* seidel@chem.ufl.edu (DS); huizhou.fan@rutgers.edu (HF)

Abstract

Sexually transmitted Chlamydia trachomatis is an extremely common infection and often leads to serious complications including infertility and pelvic inflammatory syndrome. Several broad-spectrum antibiotics are currently used to treat C. trachomatis. Although effective, they also kill beneficial vaginal lactobacilli. Two N-acylhydrazones, CF0001 and CF0002, have been shown previously to inhibit chlamydial growth without toxicity to human cells and Lactobacillus spp. Of particular significance, the rate of random mutation leading to resistance of these inhibitors appears to be extremely low. Here, we report three analogs of CF0001 and CF0002 with significantly stronger inhibitory effects on chlamydiae. Even though the new compounds (termed SF1, SF2 and SF3) displayed slightly decreased inhibition efficiencies for a rare Chlamydia variant selected for CF0001 resistance (Chlamydia muridarum MCR), they completely overcame the resistance when used at concentrations of 75–100 μM. Importantly, SF1, SF2 and SF3 did not show any toxic effect on lactobacilli, whereas SF3 was also well tolerated by human host cells. An effort to isolate SF3-resistant variants was unsuccessful. By comparison, variants resistant to rifampin or spectinomycin were obtained from smaller numbers of chlamydiae. Our findings suggest that SF3 utilizes an antichlamydial mechanism similar to that of CF0001 and CF0002, and will be more difficult for chlamydiae to develop resistance to, potentially making it a more effective antichlamydial agent.

Introduction

Chlamydiae are Gram-negative bacteria replicating only inside eukaryotic host cells [1]. Of the more than 10 Chlamydia species, C. pneumoniae and C. trachomatis are important human pathogens. C. pneumoniae is an etiologic agent of pneumonia and bronchitis, and a possible risk factor for atherosclerosis [2] and late-onset Alzheimer disease [3, 4]. Worldwide, C. trachomatis is the most prevalent sexually transmitted bacterial pathogen [5, 6]. In the US, the
number of people with sexually transmitted *C. trachomatis* infection consistently accounted for over 60% of the total number of cases of infection by some 60 different pathogens reported to the Centers for Disease Control and Prevention (CDC) in recent years [7, 8]. Yet, the CDC estimates the number of reported cases of *C. trachomatis* infection to be only one tenth of the actual number of infected people [9]. Some *C. trachomatis* serotypes cause conjunctivitis, and are the most common infectious microbe associated with blindness in various developing countries [10, 11]. Among the non-human-pathogenic chlamydiae, several are known zoonotic pathogens [12], whereas *C. muridarum* is used broadly to model human chlamydial infections in mice [13–15].

Although *C. trachomatis* is susceptible to several broad-spectrum antibiotics such as azithromycin and tetracyclines, most infected women do not seek medical treatment because they are either completely asymptomatic or only mildly symptomatic [16]. On the one hand, without proper antibiotic treatment, one-third of infected women can develop severe complications, including tubal factor infertility, pelvic inflammatory disease and ectopic pregnancy; on the other hand, treatment with broad spectrum antibiotics may lead to vaginal and gut dysbiosis [17–19]. Therefore, it is very desirable to develop antibacterials that narrowly target *Chlamydia*. Specific antichlamydials would also help reduce the risk of other bacterial pathogens developing resistance to common antibacterials.

Previous studies identified two N-acylhydrazones, CF0001 and CF0002, as specific antichlamydials [20]. While inhibiting all three *Chlamydia* species tested, *C. trachomatis*, *C. pneumoniae* and *C. muridarum*, CF0001 and CF0002 have no detectable toxicity to either host cells or vaginal lactobacilli. Another strikingly attractive feature of these two compounds is that it appears to be extremely difficult for chlamydiae to develop resistance to them. Accordingly, although a lengthy three month selection with stepwise increase in the CF0001 concentration led to isolation of a partially resistant variant, numerous repeated efforts failed to isolate additional resistant variants from *C. trachomatis* and *C. muridarum* even when mutagenized stocks were used as starting materials [20]. The high target selectivity of CF0001 and CF0002, combined with extremely low rates of resistance in chlamydiae, inspired us to develop more potent analogs. Here, we report three compounds that display increased antichlamydial activities while remaining nontoxic to vaginal lactobacilli. One of these three compounds is also highly tolerated by human host cells.

Findings from comparative susceptibility analyses in the CF0001-resistant variant and the wildtype strain predict ultralow rates of spontaneous mutation leading to resistance to this new specific antichlamydial in *C. trachomatis*.

**Results**

**Fragments of CF0002 lack antichlamydial activities**

Two N-acylhydrazones, CF0001 and CF0002 (Fig 1A), have been shown to act as specific *Chlamydia* inhibitors [20]. The mechanism underlying the inhibition is unknown. Since some, but not all, N-acylhydrazones act as prodrugs through hydrolysis into two fragments [21], we investigated the possibility that CF0002 inhibits *Chlamydia* through a hydrolytic product, F1 or F2 (Fig 1B). As expected, CF0002 demonstrated dose-dependent inhibitory effects on the number and/or the size of the *C. trachomatis* inclusion in HeLa cells starting at 25 μM; inclusions formed in the presence of 100 μM were barely detectable (Fig 1C top panel). However, chlamydial growth was only marginally affected by either F1 or F2, even at 100 μM (Fig 1C, row 2 and 3, respectively). When both F1 and F2 were added to cultures, a noticeably additive effect was only observed at 100 μM each (Fig 1C, row 4). Nonetheless, the inhibition by 100 μM F1 and 100 μM F2 combined was still weaker than that of 50 μM CF0002. These data
do not support the notion that a hydrolytic product of either CF0001 or CF0002 is responsible for their antichlamydial activity.

SF1, SF2 and SF3 are strong antichlamydials

Since neither fragment of CF0002 showed significant antichlamydial activity, we explored modifications of CF0002 and determined the effects of seven analogs (Fig 2A) on *C. trachomatis* growth (Fig 2B). Four of the derivatives (SF1, SF2, SF4 and SF7) as well as CF0002 were tested at 0, 10, 25, 50, 75 and 100 µM whereas the highest concentration tested for SF3 was 50 µM.

**Fig 1. Lack of significant antichlamydial activities in fragments of CF0002.** Structures of CF0001 and CF0002 (A) and hypothetic hydrolytic products F1 and F2 of CF0002 (B). (C) Strong inhibition of *C. trachomatis* L2 growth by CF0002 but not F1 and/or F2. HeLa cells were infected with RFP/iGFP-L2r at a multiplicity of infection (MOI) of 0.2 inclusion-forming unit per cell. Chemical treatment started 1 h postinoculation. The 0 µM cultures contained 1% DMSO in their media. 28 h postinoculation, images of chlamydial inclusions emitting red fluorescence signals as well as cellular images under bright light were acquired. A scale bar is at the bottom.

https://doi.org/10.1371/journal.pone.0185783.g001
Specific antichlamydial N-acylhydrazone
75 μM, and those for SF5 and SF6 were 50 μM due to their limited solubility in the initial solvent DMSO and subsequently in the culture medium. The apparent minimal inhibition concentrations (MIC) of SF1, SF2 and SF3 were 50 μM. In contrast, 100 μM CF0002 failed to fully prevent inclusion formation (Fig 2B). Compared with SF1, SF2 and SF3, SF4 demonstrated a slightly lower antichlamydial activity with an MIC of 75 μM. SF5 appeared to be as effective as SF4, whereas SF6 appears to be as effective as CF0002. However, the MIC for neither SF5 nor SF6 could be determined because their highest concentration tested could not exceed 50 μM. Finally, SF7 appears to be as effective as or less than CF0002 (Fig 2B).

We further quantified recoverable inclusion forming units (IFUs) from the infected cells treated with CF0002, SF1, SF2, SF3 or DMSO. These experiments revealed the minimal chlamydicidal concentrations (MCC) for SF1, SF2 and SF3 were 50 μM, whereas the MCC of CF0002 was higher than 100 μM (Fig 3). Taken together, data in both Fig 2 and Fig 3 demonstrate that SF1, SF2 and SF3 are more potent antichlamydiads than CF0002.

**CF0001- and CF0002-resistant *C. muridarum* variant MCR is cross-resistant to SF1, SF2 and SF3**

We next compared inhibition efficiencies of SF1, SF2 and SF3 in wildtype *C. muridarum* MoPn with their inhibition efficiencies in MCR to infer their antichlamydal mechanisms. MCR is an isogenic variant of MoPn, which is partially resistant to CF0001 and CF0002 [20]. The inhibition was determined by quantifying infectious EBs through immunofluorescence staining using a polyclonal anti-MoPn antibody (Fig 4A). Consistent with data obtained with *C. trachomatis* (Figs 2 & 3), SF1, SF2 and SF3 all demonstrated stronger antichlamydial activities than CF0002 for MoPn (Fig 4B). Noticeably, the new inhibitors consistently inhibited MCR less efficiently, as compared with MoPn. Nonetheless, they still fully abrogated MCR’s capacity to form progeny EBs at 75 μM (SF1 and SF3) or 100 μM (SF2) (Fig 4B).

To determine whether MCR is generally resistant to antibacterials, we determined the inhibition efficiencies of rifampin and INP0007 in MCR and MoPn. Whereas rifampin inhibits bacterial RNA synthesis [22], INP0007 interferes with chlamydial heme metabolism and also affects iron metabolism in the host cell [23]. While MoPn and MCR were equally susceptible to rifampin (Fig 4C), MCR was significantly more susceptible to INP0007 (Fig 4D), despite its lower susceptibility to CF0001, SF1, SF2 and SF3 (Fig 4A). Interestingly, MoPn and MCR were equally susceptible to iron-saturated INP0007 (Fig 4D), which presumably only interferes with chlamydial heme metabolism without affecting iron availability in the host cell. Consistent with published studies of INP compounds [23, 24], iron-saturated INP0007 at 20 μM was about 100 fold a weaker MoPn inhibitor than INP0007 (Fig 4D). Taken together, the data in Fig 4 indicate that SF1, SF2 and SF3 likely share the same antichlamydial mechanism as CF0002 (and CF0001).

**SF3 is highly tolerated by mammalian cells**

To determine effects of SF1, SF2 or SF3 on host cells, we cultured HeLa (human cervical carcinoma) cells and OK (immortalized but nonmalignant opossum kidney tubule epithelial cells) with media containing the new antichlamydiads starting with low cell confluency. Under
microscope, HeLa cells and OK cells demonstrated similar responses. Images of HeLa cells at 0, 24 and 40 h treatment are presented in Fig 5A. Compared to 1% DMSO, both 75 μM SF1 and 75 μM SF2 halted cell growth. SF2 also caused a significant proportion of cells to round up. In contrast, SF3-treated cells looked indistinguishable from control DMSO-treated cells. Results of MTT assay, which quantitatively measures metabolic activity of cells and is predictive of cell viability, corroborated microscopic observations (Fig 5B). Thus, SF3 but not SF1 and SF2 lacks toxicity to mammalian cells.

SF1, SF2 and SF3 do not inhibit \textit{Lactobacillus} growth

\textit{Lactobacilli} help protect the female genital tract from pathogens [25]. We determined the impact of SF1, SF2 and SF3 on the growth of two \textit{L. crispatus} strains and one \textit{L. jensenii} strain isolated from the vagina. Growth kinetics of all the three strains cultured in medium containing 100 μM SF1, 100 μM SF2 or 75 μM SF3 was indistinguishable from the growth kinetics of bacteria cultured in control medium (Fig 5). Similar results were also obtained with 500 μM SF1 and 500 μM SF2. As for SF3, no concentration higher than 75 μM was tested because of its limited solubility. These results suggest that like CF0001 and CF0002 [20], SF1, SF2 and SF3 inhibit chlamydiae without affecting the growth of vaginal probiotic lactobacilli even at very high concentrations.

Isolation of resistant mutants after selection with rifampin and spectinomycin but not SF3

We assessed rates of random mutations leading to resistance to SF3, rifampin and spectinomycin. Selection of rifampin- and spectinomycin-resistant mutants was initiated with a T75 flask of HeLa cells and 10⁷ IFU of MoPn EBs for each inhibitor. The MIC of rifampin was 8 ng/ml.
Fig 4. Differential susceptibilities to SF1, SF2 and SF3 in wildtype *C. muridarum* strain MoPn and the CF0001- and CF0002-resistant variant MCR. (A) L929 cells were either uninfected or infected with increased doses of MoPn EBs. 22 h postinoculation, cells were fixed, and subjected to immunofluorescence staining using a polyclonal mouse anti-MoPn antibody. A scale bar is at the bottom. (B-D) HeLa cells were infected with MoPn or MCR at a multiplicity of infection (MOI) of 0.2 inclusion-forming unit per cell. Chemical treatment started 1 h postinoculation. 24 h postinoculation, culture media were removed. Cell lysates were prepared, subjected to 1:10 serial dilution, and inoculated onto L292 cells. 22–24 h later, infected cells were fixed and chlamydial inclusions were stained with an immunofluorescence assay using the same antibody as in (A). (B) Compared to wildtype *C. muridarum* MoPn, MCR showed increased...
Selection for rifampin-resistant variants was performed with 6 ng/ml of the antibiotic. Inclusions ceased to be visible in the culture of the 7th passage, but a few inclusions reappeared in the culture of the 8th passage. Chlamydiae from this last passage were found to tolerate 32 ng/ml rifampin. Sequencing analyses revealed two nucleotide substitutions within a single codon (CAG → TAC) in the RNA polymerase β subunit gene (rpoB) in all 4 clonal populations. This specific codon switch translates to Q455Y substitution in the RpoB protein. The RpoB protein is an established target of rifampin, and mutations in this region of RpoB have been shown to cause rifampin-resistance in other bacteria [26].

The MIC of spectinomycin was 50 μg/ml. Spectinomycin-resistant variants were selected for at an inhibitor concentration 10 μg/ml. Inclusions became progressively fewer from passage 1 through passage 6, and completely undetectable in the culture of the 7th passage. After another passage with 10 μg/ml spectinomycin, 2 additional blind passages with inhibitor-free medium, inclusions reemerged. The remerging chlamydiae were found to tolerate at least 100 μg/ml spectinomycin. Sequencing of the 16S ribosomal RNA gene, a known target of spectinomycin, reveal two independent variants. One had a G→T transversion at nucleotide 134907, while the other had a C→T transition at nucleoside 135035 (as numbered in the reference genome, GenBank accession number CP007276).

Our previous studies demonstrated low rates of resistance to CF0001 and CF0002 [20]. Since the structure of SF3 (Fig 2A) closely resembles the structures of CF0001 and CF0002 (Fig 1A), we predicted that frequency of random mutation rendering resistance to SF3 is also low. Therefore, we initiated selection of SF3-resistant variants with two T150 flasks and 4 X 10^7 IFU of MoPn EBs (i.e., 4 times of the number of initial EBs that were used for the selection of rifampin- and spectinomycin-resistant variants). After successive passages with SF3 at 10 μM and 30 μM SF3 for 7 and 4 passages, respectively, no inclusions formed when the concentration increased to 50 μM, the MIC (Fig 4). No inclusions reemerged after four successive blind passages in medium free of the inhibitor. Taken together, the results of the resistant variant selection experiments support the notion that rates of resistance to SF3 is low in MoPn.

Discussion

Whereas ocular-tropic C. trachomatis remains the number one infectious cause of blindness in developing countries, urogenital-tropic C. trachomatis is unquestionably the most common sexually transmitted bacterial pathogen worldwide, and arguably the most common of all sexually transmitted pathogens. In this study, we have identified three new N-acylhydrazones (SF1, SF2 and SF3) with strong antichlamydial activities (Fig 2 and Fig 3). All three compounds are well tolerated by beneficial vaginal lactobacilli (Fig 6). SF3 is also well tolerated by host human cells (Fig 5). Thus, SF3 appears to be a safe and specific antichlamydial.

There are at least three rationales for developing new antichlamydials. First, although antibiotic resistance is currently not a clinical problem, it may become one in the future. Indeed, in the US and Europe, tetracycline-resistance is already widespread in Chlamydia suis, a porcine pathogen, following decades’ long use of tetracycline by farmers to prevent bacterial infection and promote growth of pigs [27–29]. Isolation of two C. trachomatis strains resistant to multiple antibiotics (doxycycline, azithromycin and ofloxacin) from three patients (two of whom were husband and wife) further supports the risk of emergence of antibiotic-resistant
Fig 5. Lack of toxic effects of SF3 on mammalian cells. (A) SF1 and SF2 but not SF3 apparently inhibited cell growth and cause morphological changes. HeLa cells at low confluency were treated with SF1, SF2, SF3.
human chlamydiae [30]. Fortunately, these multiple-resistant strains did not seem to spread further.

The second rationale for developing new antichlamydials is that treating chlamydial infection with current therapeutics may facilitate the occurrence of antibiotic resistance in other pathogens. Although only a small portion of people infected with *C. trachomatis* (and *C. pneumoniae*) are diagnosed and treated with antibiotics, the absolute number of infected people who receive antibiotics is still of significance, which can be regarded as an effective driver for antibiotic resistance in other pathogens. For this reason, *Chlamydia*-specific antibiotics are preferred, and likely will extend the “use lives” of existing antibiotics for some pathogens even though several lethal pathogens are already completely resistant to almost all clinical drugs.

The third rationale for developing specific antichlamydials relates to the adverse effects of broad-spectrum antibiotics on microbiotas. In most reproductive-age women, lactobacilli dominate their vaginal microbiota. Abundant evidence suggests that vaginal lactobacilli such as *L. crispatus* are required for the health of the genital tract in women. By producing lactic acid, vaginal lactobacilli maintain an acidic vaginal environment with a pH range of 2.8–4.2. Loss of vaginal lactobacilli, for example, due to broad spectrum antibiotics, may cause vaginal dysbiosis, leading to yeast vaginosis [31–36]. SF1, SF2 and SF3 are all well tolerated by vaginal lactobacilli (Fig 6). However, how they would affect other microbiotas, particularly the gut microbiota, as well as other beneficial components of the vaginal microbiota is not known. Addressing this question with certainty will require human studies for two reasons. First, most microbiota components are not cultivable. Second, humans and animals differ in microbiota composition substantially. For example, most animals have a near neutral vaginal pH. There are lactic-acid producing microbes in the lower genital tract of some non-human primates, but their vaginal pH is significantly higher than that of women.

The rate of spontaneous mutation leading to resistance is a critical aspect for antimicrobials. Previously, although a lengthy three month selection of MoPn resulted in the isolation of a partially CF0001/CF0002-resistant variant MCR, repeated efforts to isolate additional resistant variants even from *C. trachomatis* and *C. muridarum* stocks that were pretreated with the mutagen ethyl methanesulfonate failed. Compared with MoPn, MCR has four single nucleotide polymorphisms in the genome, which affect four different genes, thus suggesting that multiple mutations may be required for resistance to these inhibitors, and that MCR is an extremely rare variant [20]. SF3 (Fig 2A) has a high degree of structural resemblance with CF0001 and CF0002 (Fig 1A), suggesting that SF3 shares the same inhibition mechanism as CF0001 and CF0002 (even though the exact mechanism has yet to be defined), and therefore it would also be difficult for *Chlamydia* to develop resistance to SF3. Two additional lines of evidence support this proposition. First, the CF0001/CF0002-resistant MCR is cross resistant to SF3 but not other types of antichlamydials (Fig 4). Second, whereas rifampin- and spectinomycin-c-resistant variants were obtained when 10^7 IFU of EBs was used for each selection, no SF3-resistant variant was obtained from 4 X 10^7 IFU.

It was previously shown that MCR has a growth defect at an early developmental stage [20]. It is also interesting that MCR is more susceptible to INP0007 (Fig 4D). Although INP0007 is an inhibitor of type III secretion of Gram-negative bacteria [37] and blocks chlamydial growth [38, 39], it has a moderate toxicity to host cells [20]. The host cell toxicity of INP0007 is related to its iron-chelating activity [23, 24]. Iron depletion is an innate immune response that is
Fig 6. No effects of SF1, SF2 and SF3 on growth of vaginal Lactobacillus spp. Overnight cultures were diluted 1:100 with fresh MRS broth containing 100 µM SF1, 100 µM SF2, 75 µM SF3 or 1% DMSO. OD595 values were recorded at indicated h postinoculation. Values are averages ± standard deviations of triplicate experiments.

https://doi.org/10.1371/journal.pone.0185783.g006
activated by microbial infections [40]. Since MCR and parental MoPn are equally susceptible to the antibacterial iron-saturated INP0007 (Fig 4D) and rifampin (Fig 4C), we hypothesize that, compared to MoPn, MCR is more susceptible to INP0007-mediated iron starvation in the host cells. Thus, it is likely that increased tolerance to specific antichlamydial N-acylhydrazones is linked to decreased fitness, particularly under iron starvation.

In conclusion, we have identified a new N-acylhydrazone (SF3) that acts as specific antichlamydial, is well-tolerated by host human cells, and is not harmful to beneficial vaginal lactobacilli. Importantly, SF3 appears to share the same inhibition mechanisms as CF0001 and CF0002, yet is significantly more potent and able to overcome chlamydial resistance to CF0001 and CF0002. Thus, it should be even more difficult for chlamydiae to develop resistance to SF3. Our findings also suggest that resistance to specific antichlamydial N-acylhydrazones is linked to decreased fitness, particularly when host cells are undergoing iron starvation, which is triggered often during microbial infection. Therefore, resistance to these inhibitors may be linked to decreased pathogenicity.

Materials and methods

Chemicals

(E)-N’-(3,5-dibromo-4-hydroxybenzylidene)-4-nitrobenzohydrazide (CF0002) and (E)-N’-(3,5-dibromo-2-hydroxybenzylidene)-4-nitrobenzohydrazide (INP0007) were previously described. Iron saturated INP0007 [INP0007(IS)] was prepared by combining INP0007 and FeCl$_3$ at an equal molar ratio one hour before use. 3,5-dibromo-4-hydroxybenzaldehyde (F2) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich. Synthetic procedures and characterization data for 4-nitrobenzohydrazide (F1), (E)-N’-(3,5-dibromo-4-hydroxybenzylidene)-4-(trifluoromethyl)benzohydrazide (SF1), (E)-N’-(3,5-dibromo-4-hydroxybenzylidene)-3,5-bis(trifluoromethyl)benzohydrazide (SF2), (E)-N’-(3,5-dibromo-4-hydroxybenzylidene)-3,5-dinitrobenzohydrazide (SF3), (E)-N’-(3,5-dibromo-4-hydroxybenzylidene)-4-methoxybenzohydrazide (SF4), (E)-N’-(3,5-dibromo-4-methoxybenzylidene)-4-nitrobenzohydrazide (SF5), (E)-N’-(3,5-bis(trifluoromethyl)benzylidene)-3,5-bis(trifluoromethyl)benzohydrazide (SF6) and (E)-N’-(4-hydroxybenzylidene)-4-(trifluoromethyl)benzohydrazide (SF7) are provided as supporting information.

Host cells and culture conditions

Human cervical carcinoma HeLa cells were used for chemical inhibition tests. Mouse fibroblast L929 cells were used as reporter cells for quantifying recoverable inclusion-forming units (IFU) of elementary bodies (EBs, the infectious chlamydial cells) from the inhibition tests as well as for raising Chlamydia EB stocks. Opossum kidney (OK) cells, in addition to HeLa cells, were used for toxicity experiments. All cell lines were maintained as adherent cultures using Dulbecco-modified Eagle’s medium containing 5% (L929 and OK) or 10% (HeLa) fetal bovine serum and 20 μg/ml gentamicin. They were cultured in 37°C incubators with humidified air supplemented with 5% CO$_2$.

Chlamydia strains

RFP/iGFP-L2r was derived by transforming a plasmid-free C. trachomatis variant, named L2R [I2(25667R)] [41], with the shuttle vector pASK-GFP/mKate2-L2 [42] as previously described [43]. The transformation resulted in restoration of the C. trachomatis plasmid-encoded genes, constitutive expression of mKate, a red fluorescence protein (RFP) and expression of a green fluorescence protein that is induced with anhydrotetracycline (iGFP). Wildtype C. muridarum
strain Nigg II, traditionally known as mouse pneumonitis pathogen or MoPn) was originally purchased from ATCC [44]. MCR, an MoPn variant with a low level of resistance to CF0001 and CF0002, was previously described [20]. EB stocks were raised from L929 cells and purified with ultracentrifugation through MD-76 gradients [45].

**Chlamydia inhibition tests**

Potential antichlamydial activities in small compounds were evaluated by determining their effects on formation of chlamydial inclusions and/or progeny EBs as previously reported [20, 46, 47]. At the time of inoculation, HeLa cells were about 70% confluent. The multiplicity of infection was 0.2 inclusion-forming unit (IFU) per cell. Chemical treatment was initiated by replacement of the culture medium with fresh medium containing indicated concentrations of an inhibitor or the vehicle DMSO (final concentration: 1%) 1 h postinoculation. To determine effects of compounds on inclusion formation, life cultures of RFP/iGFP-L2r-infected life were imaged 28 h postinoculation using an Olympus monochrome CCD camera under an Olympus IX51 fluorescence microscope through the red fluorescence channel. Corresponding bright-light images were also obtained. Image processing (coloring and imaging overlay) were accomplished by using the PictureFrame software [43]. Lowest concentration of a chemical that resulted in apparent absence of chlamydial inclusion formation was defined as the minimal inhibition concentration (MIC). To determine effects of compounds on progeny EB formation, media were aspirated. Cells were scraped off the plastic, collected into 200 μL sucrose-phosphate-glutamic acid buffer and disrupted by sonication 40 h postinoculation [47]. Cell lysates were clarified by centrifugation (500 g, 10 min). Resulting supernatants were subjected to 1:10 serial dilution, and inoculated to L929 monolayers at about 90% confluence in 96-well plates. Infected L929 cells were cultured in medium containing 1 μg/mL cycloheximide to maximize chlamydial growth. 20 h postinoculation, anhydrotetracycline was added to culture medium (final concentration: 20 nM) to induce GFP expression. Green fluorescence inclusions were enumerated 30 h postinoculation under an Olympus XI-51 fluorescence microscope following fixation sequentially with paraformaldehyde and methanol as detailed previously [48]. To determine effects of compounds on progeny EB formation for MoPn- and MCR, infected cells were collected and lysed 22–24 h postinoculation. Lysates were inoculated onto L929 cells. Following 24 h incubation in medium containing 1 μg/mL cycloheximide, cells were fixed with cold methanol, and reacted sequentially with pooled sera collected from mice infected with MoPn (Kang and Fan, unpublished studies) at 1:4,000 dilution and fluorescein isothiocyanate-conjugated rabbit anti-mouse IgG (Sigma-Aldrich). Inclusions were numerated as described above. For both *C. trachomatis* and *C. muridarum*, the lowest concentration of a compound that resulted in full abrogation of progeny EB formation was defined as the minimal chlamydicidal concentration (MCC).

**Determination of host cell toxicity**

Host cell toxicity of antichlamydials was assessed by visualizing cell growth with light microscopy and by measuring cellular metabolic activities using an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay [49]. To visualize effects of compounds on cell growth, HeLa cells were seeded onto 12-well plates at 25% confluency. Treatment with antichlamydials or DMSO was initiated 5 h after seeding. At indicated times following addition of chemical compounds, cell densities were observed under a light microscope, and phase contrast images were acquired.

MTT assays were carried out using 96-well plates. HeLa and OK cells were seeded at 10% and 20% confluency, respectively. After 3 h incubation at a tissue culture incubator, the culture
medium was replaced with 90 μL (per well) phenol-red-free DMEM containing 10% fetal bovine serum and 75 μM SF1, SF2 or SF3, or 1% DMSO. At indicated times, 10 μL of a 12 mM MTT stock solution prepared in phosphate-buffered saline was added into each well. Cells were cultured for additional 4 h, and lysed by addition of 100 μL 10% (W/V) sodium dodecyl sulfate containing 10 mM HCl. After another 4 h incubation at 37˚C, plates were placed on an orbital shaker for 5 min and OD_{570} values were obtained using a plate reader.

**Determination of tolerance by Lactobacillus**

*L. crispatus* strains ATCC33197 (*L. crispatus* 33197) and ATCC33820 (*L. crispatus* strains ATCC33820) and *L. jensenii* strain ATCC25258 (*L. jensenii* 25258) were cultured with the MRS Lactobacilli broth (Sigma) in a humidified 5% CO\textsubscript{2} incubator [47]. For testing the effects of antichlamydia on lactobacilli, overnight cultures were diluted 1:100 with fresh MRS broth containing an inhibitor or vehicle DMSO on 96-well plates. OD\textsubscript{595} was measured on a plate reader at indicated times.

**Selection for resistant variants and isolation of clonal populations**

Basic procedures for selection of resistance to inhibitors have been previously described [20, 46, 47]. Clonal populations were generated from resistant chlamydiae by limiting dilution [50].

**DNA sequencing**

Sequences of the RNA polymerase β subunit gene (*rpoB*) and the 16S ribosomal RNA gene as well as their flanking regions in clones resistant to rifampin and spectinomycin, respectively, were determined using the automated fluorochrome-conjugated deoxyribonucleotide termination sequencing technique through paid service provided by Macrogen USA [20, 46].

**Supporting information**

S1 File.

(PDF)

**Acknowledgments**

We thank Dr. Guangming Zhong (University of Texas Health Sciences Center San Antonio) for the supply of *C. trachomatis* L2R [L2(25667R)] and Dr. P. Scott Hefty (University of Kansas) for the supply of pASK-GFP/mKate2-L2. DS and HF thank Dr. Eric Lam (Rutgers University) for inviting them to the 9th Tripartite Meeting held in Maresias, Brazil, where this collaboration originated. HZ and HF thank Dr. Daniel Pilch for giving us access to his plate reader, and members of the Fan Lab for helpful discussions. This work was supported by grants from the National Institutes of Health (Grant # AI122034), New Jersey Health Foundation (PC45-16) and the Busch Biomedical Research Program.

**Author Contributions**

**Conceptualization:** Daniel Seidel, Huizhou Fan.

**Data curation:** Huirong Zhang, Anuj Kunadia.

**Formal analysis:** Huirong Zhang, Anuj Kunadia, Yingfu Lin, Daniel Seidel, Huizhou Fan.

**Funding acquisition:** Huizhou Fan.
Investigation: Huirong Zhang, Anuj Kunadia, Yingfu Lin.
Methodology: Huirong Zhang, Anuj Kunadia, Yingfu Lin, Daniel Seidel, Huizhou Fan.
Project administration: Daniel Seidel, Huizhou Fan.
Resources: Joseph D. Fondell, Daniel Seidel, Huizhou Fan.
Supervision: Daniel Seidel, Huizhou Fan.
Validation: Huirong Zhang, Anuj Kunadia, Yingfu Lin.
Visualization: Huirong Zhang, Anuj Kunadia, Yingfu Lin.
Writing – original draft: Anuj Kunadia, Huizhou Fan.
Writing – review & editing: Huirong Zhang, Anuj Kunadia, Yingfu Lin, Joseph D. Fondell, Daniel Seidel, Huizhou Fan.

References

1. Stephens RS, Myers G, Eppinger M, Bavoil PM. Divergence without difference: phylogenetics and taxonomy of Chlamydia resolved. FEMS Immunol Med Microbiol. 2009; 55(2):115–9. Epub 2009/03/14. https://doi.org/10.1111/j.1574-695X.2008.00516.x PMID: 19281563.

2. Campbell LA, Kuo CC, Grayston JT. Chlamydia pneumoniae and cardiovascular disease. Emerg Infect Dis. 1998; 4(4):571–9. Epub 1998/12/29. https://doi.org/10.3201/eid0404.980407 PMID: 9866733; PubMed Central PMCID: PMC2640250.

3. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging. 2004; 25(4):419–29. Epub 2004/03/12. https://doi.org/10.1016/S0197-4580(03)00127-1 PMID: 15013562.

4. Balin BJ, Little CS, Hammond CJ, Appelt DM, Whittum-Hudson JA, Gerard HC, et al. Chlamydomphila pneumoniae and the etiology of late-onset Alzheimer’s disease. J Alzheimers Dis. 2008; 13(4):371–80. Epub 2008/05/20. PMID: 18487846.

5. CDC. CDC fact sheet. STD trends in the United States: 2011 national data for chlamydia, gonorrhea, and syphilis. 2013.

6. CDC. CDC fact sheet. STD trends in the United States: 2013 national data for chlamydia, gonorrhea, and syphilis. 2014.

7. Adams DA, Thomas KR, Jajosky RA, Foster L, Sharp P, Onweh DH, et al. Summary of Notifiable Infectious Diseases and Conditions—United States, 2014. MMWR Morbidity and mortality weekly report. 2016; 63(54):1–152. PMID: 27736829.

8. Adams D, Fullerton K, Jajosky R, Sharp P, Onweh D, Schley A, et al. Summary of Notifiable Infectious Diseases and Conditions—United States, 2013. MMWR Morbidity and mortality weekly report. 2015; 62(53):1–122. https://doi.org/10.15585/mmwr.mm6253a1 PMID: 26492038.

9. CDC. Notifiable Diseases and Mortality Tables. Morb Mortal Wkly Rep. 2013; 62(31):424–37.

10. Fan H. Blindness-causing trachomatous trichiasis biomarkers sighted. Invest Ophthalmol Vis Sci. 2012; 53(6):2560. https://doi.org/10.1167/iovs.12-9835

11. Burton MJ, Mabey DCW. The global burden of trachoma: a review. PLoS Negl Trop Dis. 2009; 3(10):e460. https://doi.org/10.1371/journal.pntd.0000460 PMID: 19869534

12. Rohde G, Straube E, Essig A, Reinhold P, Sachse K. Chlamydial Zoonoses. Deutsches Arzteblatt International. 2010; 107(10):174–80. https://doi.org/10.3238/arztebl.2010.0174 PMID: 20358033

13. de la Maza L, Pal S, Khamesipour A, Peterson E. Intravaginal inoculation of mice with the Chlamydia trachomatis mouse pneumonitis biovar results in infertility. Infect Immun. 1994; 62(5):2094–7. PMID: 8168974

14. Cotter TW, Miranpuri GS, Ramsey KH, Poulsen CE, Byrne GI. Reactivation of chlamydial genital tract infection in mice. Infect Immun 1997; 65(6):2067–73. PMID: 9169733

15. Chen L, Lei L, Chang X, Li Z, Lu C, Zhang X, et al. Mice deficient in MyD88 Develop a Th2-dominant response and severe pathology in the upper genital tract following Chlamydia muridarum infection. J Immunol. 2010; 184(5):2602–10. Epub 2010/02/04. https://doi.org/10.4049/jimmunol.0901593 PMID: 20124098.
16. Schachter J. Infection and disease epidemiology. p.139–169 In Stephens R. S. (Ed.),. Chlamydia Intracellular Biology, Pathogenesis, ASM Press, Washington DC. 1999.

17. Hill LV, Embil JA. Vaginitis: current microbiologic and clinical concepts. CMAJ: Canadian Medical Association Journal. 1986; 134(4):321–31. Epub 1986/02/15. PMID: 3510698; PubMed Central PMCID: PMC1490817.

18. Keeney KM, Yurist-Douglas S, Arrieta MC, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol. 2014; 68:217–35. https://doi.org/10.1146/annurev-micro-091313-103456 PMID: 24995874.

19. Lange K, Buerger M, Stallmach A, Bruns T. Effects of Antibiotics on Gut Microbiota. J Infect Dis. 2001; 183(5):1189–90. PMID: 11385144.

20. Bao X, Gylfe A, Sturdevant GL, Gong Z, Xu S, Caldwell HD, et al. Benzylidene acylhydrazides inhibit chlamydial growth in a type III secretion- and iron chelation-independent manner. J Bacteriol. 2014; 196(16):2989–3001. Epub 2014/06/11. https://doi.org/10.1128/JB.01677-14 PMID: 24914180.

21. Dutra LA, de Almeida L, Passalacqua TG, Reis JS, Torres FAE, Martinez I, et al. Leishmanicidal Activities of Novel Synthetic Furoxan and Benzofuroxan Derivatives. Antimicrob Agents Chemother. 2014; 58(8):4837–47. https://doi.org/10.1128/AAC.00052-14 PMID: 24913171.

22. Knight JL, Mekler V, Mukhopadhyay J, Ebright RH, Levy RM. Distance-restricted docking of rifampicin and rifamycin SV to RNA polymerase using systematic FRET measurements: developing benchmarks of model quality and reliability. Biophys J. 2005; 88(2):925–38. Epub 2004/11/16. https://doi.org/10.1529/biophysj.104.050187 PMID: 15542547; PubMed Central PMCID: PMC1305165.

23. Engstrom P, Nguyen BD, Normark J, Nilsson I, Bastidas RJ, Gylfe A, et al. Mutations in hemG mediate resistance to salicylidene acylhydrazides, demonstrating a novel link between protoporphyrinogen oxidase (HemG) and Chlamydia trachomatis infectivity. J Bacteriol. 2013; 195(18):4221–30. https://doi.org/10.1128/JB.00506-13 PMID: 23852872; PubMed Central PMCID: PMC3754756.

24. Slepenkin A, Enquist PA, Hagglund U, de la Maza LM, Elofsson M, Petersson EM. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun. 2007; 75(7):3478–89. https://doi.org/10.1128/IAI.00023-07 PMID: 17470544.

25. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SSK, McCulle SL, et al. Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA. 2011; 108(Supplement 1):4680–7. https://doi.org/10.1073/pnas.1002611107 PMID: 20534435.

26. Srivastava A, Degen D, Ebright YW, Ebright RH. Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus. Antimicrob Agents Chemother. 2012; 56(12):6250–5. Epub 2012/09/26. https://doi.org/10.1128/AAC.00506-12 PMID: 23006749; PubMed Central PMCID: PMC3497154.

27. Joseph SJ, Marti H, Didelot X, Read TD, Dean D. Tetracycline Selective Pressure and Homologous Recombination Shape the Evolution of Chlamydia suis: A Recently Identified Zoonotic Pathogen. Genome Biol Evol. 2016; 8(8):2613–23. https://doi.org/10.1093/gbe/evw182 PMID: 27576537; PubMed Central PMCID: PMC497154.

28. Lenart J, Andersen AA, Rockey DD. Growth and development of tetracycline-resistant Chlamydia suis. Antimicrob Agents Chemother. 2001; 45(8):2198–203. https://doi.org/10.1128/AAC.45.8.2198-2203.2001 PMID: 11451674.

29. Borel N, Regenscheid N, Di Francesco A, Donati M, Markov J, Masserey Y, et al. Selection for tetracycline-resistant Chlamydia suis in treated pigs. Vet Microbiol. 2012; 156(1–2):143–6. https://doi.org/10.1016/j.vetmic.2011.10.011 PMID: 22036200.

30. Somani J, Bhullar VB, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis. 2000; 181(4):1421–7. https://doi.org/10.1086/315372 PMID: 10762573.

31. Donders GG, Bellien G, Mendling W. Management of recurrent vulvo-vaginal candidosis as a chronic illness. Gynecologic and obstetric investigation. 2010; 70(4):306–21. https://doi.org/10.1159/000314022 PMID: 21051852.

32. Martin HL Jr., Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis. 1998; 178(4):1053–9. PMID: 9806034.

33. Pirotta MV, Garland SM. Genital Candida species detected in samples from women in Melbourne, Australia, before and after treatment with antibiotics. J Clin Microbiol. 2006; 44(8):3213–7. https://doi.org/10.1128/JCM.00218-06 PMID: 16954250; PubMed Central PMCID: PMC1594690.

34. Dan M, Kaneti N, Levin D, Poch F, Samra Z. Vaginitis in a gynecologic practice in Israel: causes and risk factors. Isr Med Assoc J. 2003; 5(9):629–32. PMID: 14509151.
35. Shapiro RA, Schubert CJ, Siegel RM. Neisseria gonorrhea infections in girls younger than 12 years of age evaluated for vaginitis. Pediatrics. 1999; 104(6):e72. PMID: 10586006.

36. Spinillo A, Capuzzo E, Acciano S, De Santolo A, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvo-vaginal candidiasis. Am J Obstet Gynecol. 1999; 180(1 Pt 1):14–7. PMID: 9914570.

37. Kauppi AM, Nordfelth R, Hagglund U, Wolf-Watz H, Elofsson M. Salicylanilides are potent inhibitors of type III secretion in Yersinia. Adv Exp Med Biol. 2003; 529:97–100. Epub 2003/05/22. https://doi.org/10.1007/0-306-48416-1_17 PMID: 12756735.

38. Muschiol S, Bailey L, Gyffe A, Sundin C, Hultenby K, Bergstrom S, et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A. 2006; 103(39):14566–71. https://doi.org/10.1073/pnas.0606412103 PMID: 16973741.

39. Wolf K, Betts HJ, Chellas-Gery B, Hower S, Linton CN, Fields KA. Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol. 2006; 61(6):1543–55. https://doi.org/10.1111/j.1365-2958.2006.05347.x PMID: 16968227.

40. Bullen JJ. The significance of iron in infection. Rev Infect Dis. 1981; 3(6):1127–38. PMID: 7043704.

41. Peterson EM, Markoff BA, Schachter J, de la Maza LM. The 7.5-kb plasmid present in Chlamydia trachomatis is not essential for the growth of this microorganism. Plasmid. 1990; 23(2):144–8. Epub 1990/03/01. PMID: 2362949.

42. Wickstrum J, Sammons LR, Restivo KN, Hefty PS. Conditional gene expression in Chlamydia trachomatis using the tet system. PLoS One. 2013; 8(10):e76743. Epub 2013/10/12. https://doi.org/10.1371/journal.pone.0076743 PMID: 24116144; PubMed Central PMCID: PMC3792055.

43. Xu S, Battaglia L, Bao X, Fan H. Chloramphenicol acetyltransferase as a selection marker for chlamydial transformation. BMC Res Notes. 2013; 6:377. Epub 2013/09/26. https://doi.org/10.1186/1756-0500-6-377 PMID: 24060200.

44. Balakrishnan A, Wang L, Li X, Ohman-Strickland P, Malatesta P, Fan H. Inhibition of chlamydial infection in the genital tract of female mice by topical application of a peptide deformylase inhibitor. Microbiol Res. 2009; 164(3):338–46. https://doi.org/10.1016/j.micres.2007.05.002 PMID: 17936604.

45. Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981; 31(3):1161–76. PMID: 7228399.

46. Bao X, Pachikara ND, Oey CB, Balakrishnan A, Westblade LF, Tan M, et al. Non-coding nucleotides and amino acids near the active site regulate peptide deformylase expression and inhibitor susceptibility in Chlamydia trachomatis. Microbiology. 2011; 157(9):2569–81. https://doi.org/10.1099/mic.0.049668-0

47. Balakrishnan A, Patel B, Sieber SA, Chen D, Pachikara N, Zhong G, et al. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem. 2006; 281(24):16691–9. https://doi.org/10.1074/jbc.M513648200 PMID: 16565079

48. Gong Z, Luna Y, Yu P, Fan H. Lactobacilli inactivate Chlamydia trachomatis through lactic acid but not H2O2. PLoS One. 2014; 9(9):e107758. https://doi.org/10.1371/journal.pone.0107758 PMID: 25215504.

49. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods. 1983; 65(1):55–63. https://doi.org/10.1016/0022-1759(83)90303-4

50. Mueller KE, Fields KA. Application of beta-lactamase reporter fusions as an indicator of effector protein secretion during infections with the obligate intracellular pathogen Chlamydia trachomatis. PLoS One. 2015; 10. https://doi.org/10.1371/journal.pone.0135295 PMID: 26258949